The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 18, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 18.
Number 5: Dr Stanley Cohen, medical director of the Metroplex Clinical Research Center and clinical professor of internal medicine at the University of Texas Southwestern Medical School, says that patients should feel comfortable about using biosimilars to treat rheumatic diseases.
Number 4: A recent paper concludes that low-level anti-tumor necrosis factor anti-drug antibodies in patients with inflammatory bowel disease may be overcome by dose escalation or the addition of an immunomodulator.
Number 3: An international, multidisciplinary task force has released 8 consensus recommendations for the use of biosimilars to treat rheumatic diseases.
Number 2: On Wednesday, Pfizer filed suit against Johnson and Johnson in a Pennsylvania district court. Pfizer’s complaint alleges that the Remicade sponsor has been using anti-competitive means to block sales of its biosimilar infliximab, Inflectra.
Number 1: Dr Angus Worthing, practicing rheumatologist and vice chair of the Alliance for Transparent and Affordable Prescriptions, says that rebates for reference biologics reduce competition and lead to higher drug prices for patients.
Finally, last week, our newsletter asked for your input on the size of the cost-saving potential that biosimilar filgrastim provides to health plans. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Pharmacokinetic Modeling Proposes Cost-Effective Dosing for Adalimumab, Etanercept Biosimilars
October 12th 2024A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.